Supplementary Data for: Efficacy and safety of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open label extension period of the Phase 2 STRIDE study

This dataset contains supplementary data for the following publication: Efficacy and safety of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open label extension period of the Phase 2 STRIDE study published in the Journal of the American Academy of Dermatology. Supplementary material includes study design details, patient eligibility criteria, list of investigators, 2 supplementary tables, and 5 supplementary figures.